FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008574713> ?p ?o ?g. }

• W2008574713 endingPage "766" @default.
• W2008574713 startingPage "766" @default.
• W2008574713 abstract "The long-term risk for fatal pulmonary embolism (PE) after treatment of venous thromboembolism (VTE) may be an important factor in the decision to discontinue this treatment.To provide reliable and precise estimates of the annual risk for fatal PE and the case-fatality rate of disease recurrence and to assess these outcomes according to the initial presentation of VTE (deep venous thrombosis [DVT], PE, or both) and its etiology (secondary or idiopathic) in patients who have discontinued anticoagulant therapy.Prospective cohort study.Academic medical centers.Inception cohort of patients with a first episode of symptomatic VTE who discontinued anticoagulant therapy.Incidence rates of any fatal PE (which included sudden death from possible fatal PE) and definite or probable PE per 100 person-years of follow-up and case-fatality rate of recurrent VTE.Of 2052 patients studied, 1450 had DVT, 310 had PE, and 292 had DVT and PE. The mean duration of previous anticoagulant therapy was 6 months (range, 3 to 39 months), and the mean duration of follow-up after discontinuation of treatment was 54 months (range, 1 to 120 months). The annual risk for any fatal PE and definite or probable fatal PE after discontinuation of anticoagulation was 0.49 events (95% CI, 0.36 to 0.64 events) per 100 person-years and 0.19 events (CI, 0.12 to 0.30 events) per 100 person-years, respectively. The case-fatality rate of recurrent disease was 9.0% (CI, 6.8% to 11.8%) for any fatal PE and 3.8% (CI, 2.4% to 5.9%) for definite or probable fatal PE.The findings are less pertinent to patients with active cancer, permanent immobility, or high-risk thrombophilia.The risk for fatal PE is 0.19 to 0.49 events per 100 person-years for patients who have finished a course of anticoagulant therapy for a first episode of symptomatic VTE. The case-fatality rate for death from recurrent PE is 4% to 9%. This information helps to inform patient prognosis and may assist clinicians in deciding whether to discontinue anticoagulant therapy for VTE." @default.
• W2008574713 created "2016-06-24" @default.
• W2008574713 creator A5011151808 @default.
• W2008574713 creator A5017418196 @default.
• W2008574713 creator A5040991094 @default.
• W2008574713 creator A5067095323 @default.
• W2008574713 creator A5069466103 @default.
• W2008574713 creator A5083115765 @default.
• W2008574713 date "2007-12-04" @default.
• W2008574713 modified "2023-10-14" @default.
• W2008574713 title "The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism" @default.
• W2008574713 cites W1589194386 @default.
• W2008574713 cites W1978280229 @default.
• W2008574713 cites W1991821845 @default.
• W2008574713 cites W1997277648 @default.
• W2008574713 cites W2022713742 @default.
• W2008574713 cites W2029339882 @default.
• W2008574713 cites W2031127066 @default.
• W2008574713 cites W2042044265 @default.
• W2008574713 cites W2047986798 @default.
• W2008574713 cites W2067741035 @default.
• W2008574713 cites W2078285144 @default.
• W2008574713 cites W2079014760 @default.
• W2008574713 cites W2087646765 @default.
• W2008574713 cites W2089435005 @default.
• W2008574713 cites W2102535207 @default.
• W2008574713 cites W2102778065 @default.
• W2008574713 cites W2120418228 @default.
• W2008574713 cites W2130373985 @default.
• W2008574713 cites W2134355273 @default.
• W2008574713 cites W2139945356 @default.
• W2008574713 cites W2150666115 @default.
• W2008574713 cites W2156573757 @default.
• W2008574713 cites W2158086311 @default.
• W2008574713 cites W2158662386 @default.
• W2008574713 cites W2160022765 @default.
• W2008574713 cites W2332640098 @default.
• W2008574713 cites W2405890773 @default.
• W2008574713 cites W3205014061 @default.
• W2008574713 cites W2019591415 @default.
• W2008574713 doi "https://doi.org/10.7326/0003-4819-147-11-200712040-00007" @default.
• W2008574713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18056660" @default.
• W2008574713 hasPublicationYear "2007" @default.
• W2008574713 type Work @default.
• W2008574713 sameAs 2008574713 @default.
• W2008574713 citedByCount "208" @default.
• W2008574713 countsByYear W20085747132012 @default.
• W2008574713 countsByYear W20085747132013 @default.
• W2008574713 countsByYear W20085747132014 @default.
• W2008574713 countsByYear W20085747132015 @default.
• W2008574713 countsByYear W20085747132016 @default.
• W2008574713 countsByYear W20085747132017 @default.
• W2008574713 countsByYear W20085747132018 @default.
• W2008574713 countsByYear W20085747132019 @default.
• W2008574713 countsByYear W20085747132020 @default.
• W2008574713 countsByYear W20085747132021 @default.
• W2008574713 countsByYear W20085747132022 @default.
• W2008574713 countsByYear W20085747132023 @default.
• W2008574713 crossrefType "journal-article" @default.
• W2008574713 hasAuthorship W2008574713A5011151808 @default.
• W2008574713 hasAuthorship W2008574713A5017418196 @default.
• W2008574713 hasAuthorship W2008574713A5040991094 @default.
• W2008574713 hasAuthorship W2008574713A5067095323 @default.
• W2008574713 hasAuthorship W2008574713A5069466103 @default.
• W2008574713 hasAuthorship W2008574713A5083115765 @default.
• W2008574713 hasConcept C107130276 @default.
• W2008574713 hasConcept C120665830 @default.
• W2008574713 hasConcept C121332964 @default.
• W2008574713 hasConcept C126322002 @default.
• W2008574713 hasConcept C141071460 @default.
• W2008574713 hasConcept C187212893 @default.
• W2008574713 hasConcept C187316915 @default.
• W2008574713 hasConcept C188816634 @default.
• W2008574713 hasConcept C207103383 @default.
• W2008574713 hasConcept C2776265017 @default.
• W2008574713 hasConcept C2778205648 @default.
• W2008574713 hasConcept C2778715236 @default.
• W2008574713 hasConcept C2780011451 @default.
• W2008574713 hasConcept C2780868729 @default.
• W2008574713 hasConcept C44249647 @default.
• W2008574713 hasConcept C61511704 @default.
• W2008574713 hasConcept C71924100 @default.
• W2008574713 hasConcept C72563966 @default.
• W2008574713 hasConceptScore W2008574713C107130276 @default.
• W2008574713 hasConceptScore W2008574713C120665830 @default.
• W2008574713 hasConceptScore W2008574713C121332964 @default.
• W2008574713 hasConceptScore W2008574713C126322002 @default.
• W2008574713 hasConceptScore W2008574713C141071460 @default.
• W2008574713 hasConceptScore W2008574713C187212893 @default.
• W2008574713 hasConceptScore W2008574713C187316915 @default.
• W2008574713 hasConceptScore W2008574713C188816634 @default.
• W2008574713 hasConceptScore W2008574713C207103383 @default.
• W2008574713 hasConceptScore W2008574713C2776265017 @default.
• W2008574713 hasConceptScore W2008574713C2778205648 @default.
• W2008574713 hasConceptScore W2008574713C2778715236 @default.
• W2008574713 hasConceptScore W2008574713C2780011451 @default.
• W2008574713 hasConceptScore W2008574713C2780868729 @default.
• W2008574713 hasConceptScore W2008574713C44249647 @default.

• next